Lucid Diagnostics (LUCD) Set to Post Earnings on Thursday

Lucid Diagnostics (NASDAQ:LUCD) is expected to release its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of ($0.06) per share and revenue of $1.63 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:30 AM ET.

Lucid Diagnostics (NASDAQ:LUCD) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06). The company had revenue of $1.47 million for the quarter, compared to analysts’ expectations of $1.43 million. On average, analysts expect Lucid Diagnostics to post ($0.29) EPS for the current fiscal year and ($0.20) EPS for the next fiscal year.

Lucid Diagnostics Stock Performance

Lucid Diagnostics stock opened at $0.40 on Wednesday. The stock’s fifty day moving average is $0.63 and its two-hundred day moving average is $1.00. Lucid Diagnostics has a 1-year low of $0.30 and a 1-year high of $1.63.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Weiss Ratings lowered Lucid Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 18th. Needham & Company LLC reissued a “buy” rating on shares of Lucid Diagnostics in a report on Thursday, October 1st. Finally, BTIG Research reissued a “buy” rating on shares of Lucid Diagnostics in a research report on Friday, October 23rd. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $4.19.

About Lucid Diagnostics

Lucid Diagnostics Inc. (NASDAQ: LUCD) is a medical diagnostics company focused on improving the detection of esophageal disease. The company develops and commercializes diagnostic technologies intended to identify patients at elevated risk of esophageal cancer, particularly those with gastroesophageal reflux disease (GERD). Lucid’s principal products include EsoGuard, a laboratory-developed DNA test that analyzes cells collected from the esophagus for molecular changes associated with Barrett’s esophagus and esophageal cancer risk, and EsoCheck, a swallowable, balloon-based device designed to collect cells from the esophageal lining.